Is clx a good investment

``` The deep research logic is organized as follows: Okay, let's tackle whether CLX is a good investment. First, I need to look at the data provided in the references. The user is asking if CLX is a good investment, so I should consider both fundamental and technical factors, as well as recent news and analyst opinions. Starting with the financials from References 1-3: CLX has a revenue of $1.99B, net income of $336M, and diluted EPS of $2.68. The revenue growth is 4.47% YoY, which is positive but not stellar. Net income growth is 52.04%, which is impressive, and EPS growth is 54.91%. However, the 3-year CAGR for revenue is negative (-1.95%), which is concerning. Net income and EPS CAGRs are 126.23% and 133.1%, respectively, showing strong growth over the past three years. The dividend yield is 3.97%, which is attractive, especially with a 44-year dividend growth streak. That's a solid sign of financial health. Looking at technical indicators from References 6-9: The MACD is 0.05, RSI is 60.48, KDJ is 71.03, and Bollinger Bands are at 123.25. The RSI is neutral, and the KDJ is in the overbought zone. The Bollinger Bands show the stock price near the upper band, which might indicate short-term overextension. Moving averages (20-day, 60-day, 250-day) are all around $123-143, with the stock price at $124.44. The 250-day MA is higher than the current price, suggesting a bearish trend in the long term. Fund flow data from Reference 10 shows net fund flow of $2.03M and block orders of $724,908.24. This indicates some institutional activity, but the amounts aren't huge, so maybe not a strong signal. Analyst price targets from Reference 11 have a range from $119 to $140, with an average of around $132.8. The current price is $124.44, so there's potential upside. However, the consensus rating is mixed, with some holds and a few sells. Recent news (References 12-14) mentions mixed signals, with some analysts看好 the dividend strength but cautioning about revenue headwinds and technical weakness. The SWOT analysis (References 12, 42) highlights strengths like brand equity and dividend history but points out challenges like retailer destocking and digital transformation efforts. The company is investing in digital marketing and operational efficiency, which could be a long-term positive but might not show immediate results. Comparing to peers (Reference 36), CLX has a lower P/E ratio (18.78) compared to industry averages, which could indicate undervaluation. However, some peers like CHD and WDFC have higher P/Es, suggesting CLX might be undervalued relative to competitors. The user's profile shows a mix of bond, tech, healthcare, and consumer staples exposure. CLX fits into the consumer staples sector, which is typically defensive. The user prefers high-profitability growth stocks and technically strong stocks. CLX's strong EPS and net income growth fit the profitability aspect, but the technicals are mixed. The dividend yield aligns with the user's interest in income-generating stocks. Putting it all together: CLX has strong fundamentals with high profitability and a reliable dividend, but faces challenges in revenue growth and technical resistance. The mixed analyst ratings and recent fund flows suggest uncertainty. The user's portfolio includes consumer staples like UNH, so adding CLX could diversify within that sector. However, the short-term technicals and revenue headwinds might be a concern for a short-term holder. The dividend and defensive nature make it a good hold, but the upside potential based on analyst targets is moderate. The user's preference for high-profitability and undervalued stocks might find CLX appealing, but caution is needed due to the mixed signals. ``` ### **Conclusion** **The Clorox Company (CLX)** presents a mixed picture as an investment opportunity, balancing **strong profitability, dividend strength, and defensive characteristics** against **revenue headwinds, technical resistance, and mixed analyst sentiment**. Here’s a detailed breakdown to help you decide: --- ### 📊 **Key Data Snapshot** | Metric | Value (Q4 2025) | Key Takeaway | |----------------------------|---------------------------------------|------------------------------------------------------------------------------| | **Revenue** | $1.99B (4.47% YoY growth) | Moderate growth, but 3-year CAGR is negative (-1.95%) | | **Net Income** | $336M (52.04% YoY growth) | Strong profitability, with 3-year CAGR of 126.23% | | **Diluted EPS** | $2.68 (54.91% YoY growth) | High profitability, 3-year CAGR of 133.1% | | **Dividend Yield** | 3.97% (44-year growth streak) | Attractive income play, but payout ratio is 76.07% | | **Price Target** | $119–$140 (avg: $132.8) | Moderate upside potential (8.7% from $124.44) | | **Technical Score** | Neutral (RSI: 60.48, KDJ: 71.03) | Overbought short-term, but long-term resistance at $143.71 | |code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code| |---|---|---|---|---|---|---|---| |CLX|CLX.N|The Clorox|2025 Q1|312|27.12842712842713|370.5882352941176|169| |CLX|CLX.N|The Clorox|2025 Q2|102.08333333333333|-15.27638190954774|105.33333333333334|169| |CLX|CLX.N|The Clorox|2025 Q3|482|-8.04851157662624|465.8536585365853|169| |CLX|CLX.N|The Clorox|2025 Q4|52.03619909502263|4.466631634261692|54.913294797687875|169| |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |CLX|CLX.N|The Clorox|2025 Q1|27.12842712842713|1.762E9|169| |CLX|CLX.N|The Clorox|2025 Q2|-15.27638190954774|1.686E9|169| |CLX|CLX.N|The Clorox|2025 Q3|-8.04851157662624|1.668E9|169| |CLX|CLX.N|The Clorox|2025 Q4|4.466631634261692|1.988E9|169| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |CLX|CLX.N|The Clorox|2025 Q1|312|1.03E8|169| |CLX|CLX.N|The Clorox|2025 Q2|102.08333333333333|1.94E8|169| |CLX|CLX.N|The Clorox|2025 Q3|482|1.91E8|169| |CLX|CLX.N|The Clorox|2025 Q4|52.03619909502263|3.36E8|169| |code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code| |---|---|---|---|---|---|---| |CLX|CLX.N|The Clorox|2025 Q1|370.5882352941176|0.8|169| |CLX|CLX.N|The Clorox|2025 Q2|105.33333333333334|1.54|169| |CLX|CLX.N|The Clorox|2025 Q3|465.8536585365853|1.5|169| |CLX|CLX.N|The Clorox|2025 Q4|54.913294797687875|2.68|169| --- ### 📊 **Why CLX Could Be a Good Investment** 1. **Defensive Profile**: - CLX operates in the **consumer staples sector**, offering **cleaning and household products** with **high inelastic demand**. - The **44-year dividend growth streak** (3.97% yield) makes it a **reliable income generator** . 2. **Profitability Excellence**: - **ROE (TTM): 377.86%**, **ROA: 6.0%**, and **Return on Capital: 21.7%** —all superior to industry peers . - **Gross Margin**: 46.5% (Q4 2025) , reflecting strong pricing power and cost efficiency . 3. **Undervalued Relative to Peers**: - **P/E (TTM): 18.78**, below industry average (23.43) . - **Price-to-Sales Ratio: 2.14**, cheaper than peers like Procter & Gamble (2.9) . 4. **Strategic Initiatives**: - **Digital Transformation**: CLX is investing in **e-commerce, AI, and data analytics** to drive **3–5% sales growth** . - **Sustainability Focus**: The **IGNITE strategy** targets **carbon neutrality** and **product innovation** . --- ### 🚨 **Why to Exercise Caution** 1. **Revenue Headwinds**: - **Q1 2026 Guidance**: Lower end of the range due to **retailer destocking** and **tariff pressures** . - **3-Year Revenue CAGR**: -1.95% , signaling stagnation in core markets. 2. **Technical Weakness**: - **RSI (60.48)** and **KDJ (71.03)** indicate **overbought conditions** . - **Bollinger Bands**: Price ($124.44) near the **upper band ($123.25)**, suggesting short-term resistance . 3. **Mixed Analyst Sentiment**: - **Consensus Rating**: Neutral (avg price target: $132.8) . - **Risks**: **Competition** from private-label brands and **supply chain disruptions** . 4. **Debt Concerns**: - **Debt-to-Equity Ratio**: 8.97x (above industry average) . - **Interest Coverage**: Declined to 3.64x (2023) . --- ### 📊 **Final Take** **CLX is a Hold for income-focused, risk-averse investors** with a **long-term horizon**. The stock offers **defensive stability** and **high profitability**, but **short-term risks** (revenue stagnation, technical resistance) and **moderate upside** (8.7% from price targets) make it less appealing for **growth-focused or speculative investors**. If you’re looking for **dividend income** and **sector diversification** (consumer staples), CLX fits your portfolio. However, **wait for a pullback** (target: $120–$122) before entering, as the stock appears overbought in the short term. **Final Rating**: 🟡 **Hold** (Neutral) **Price Target**: $132–$135 (10–15% upside) .